Fulcrum Therapeutics adds accounting duties to CFO

Fulcrum Therapeutics, Inc. reported an executive leadership change in its finance organization.

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. reported an executive leadership change in its finance organization. Vice President, Finance and principal accounting officer Greg Tourangeau, whose planned departure had been previously disclosed, will end his tenure on August 7, 2026. Effective the same date, the Board appointed chief financial officer and principal financial officer Alan Musso to also serve as principal accounting officer.

Musso’s background is described in the company’s definitive proxy statement filed on April 30, 2026. He will not receive additional compensation for assuming the principal accounting officer role. The company states there is no arrangement or understanding with any person regarding his appointment, no family relationships with other directors or executive officers, and no related-party transactions involving Musso that require disclosure under Item 404(a) of Regulation S-K.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Tourangeau departure date: August 7, 2026 Musso appointment effective date: August 7, 2026 Proxy filing date: April 30, 2026

3 metrics

Tourangeau departure date August 7, 2026 Date Greg Tourangeau’s tenure as VP Finance and principal accounting officer ends

Musso appointment effective date August 7, 2026 Effective date of Alan Musso’s appointment as principal accounting officer

Proxy filing date April 30, 2026 Date of definitive proxy statement incorporating Musso’s biographical information

Key Terms

principal accounting officer, definitive proxy statement, Item 404(a) of Regulation S-K

3 terms

principal accounting officer financial

"appointed Alan Musso ... as principal accounting officer, effective August 7, 2026"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

definitive proxy statement regulatory

"Biographical information for Mr. Musso is set forth in Fulcrum’s definitive proxy statement"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Item 404(a) of Regulation S-K regulatory

"does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Fulcrum Therapeutics (FULC) announce in its finance organization?

Fulcrum Therapeutics announced that Greg Tourangeau, Vice President, Finance and principal accounting officer, will depart, and Alan Musso, the current chief financial officer, has been appointed principal accounting officer effective August 7, 2026, consolidating key finance responsibilities under one executive.

When will Greg Tourangeau leave his role at Fulcrum Therapeutics (FULC)?

Greg Tourangeau’s tenure as Vice President, Finance and principal accounting officer at Fulcrum Therapeutics will end on August 7, 2026. His departure had been mutually agreed earlier and previously disclosed, and the company has aligned the effective date with the new appointment.

What new responsibility did CFO Alan Musso assume at Fulcrum Therapeutics (FULC)?

Chief financial officer Alan Musso has been appointed principal accounting officer of Fulcrum Therapeutics, effective August 7, 2026. He will serve simultaneously as CFO, principal financial officer, and principal accounting officer, with no additional compensation for this expanded role.

Will Fulcrum Therapeutics (FULC) pay additional compensation to Alan Musso for his new role?

Fulcrum Therapeutics states that Alan Musso will not receive any additional compensation in connection with his appointment as principal accounting officer. His new responsibilities are in addition to his existing roles as chief financial officer and principal financial officer.

Are there related-party or family relationships tied to Alan Musso’s appointment at Fulcrum Therapeutics (FULC)?

The company reports there are no family relationships between Alan Musso and any directors or executive officers, and that Musso has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 08:43 AM EDT Learn about SEC filing dates

0001680581false00016805812026-08-072026-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2026

Fulcrum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-38978	47-4839948
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
26 Landsdowne Street
Cambridge, Massachusetts				02139
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 651-8851

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		FULC		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed with Fulcrum that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed. Fulcrum and Mr. Tourangeau have agreed that his tenure in such roles will end on August 7, 2026.

In light thereof, on August 9, 2026, Fulcrum’s Board of Directors appointed Alan Musso, Fulcrum’s chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau’s departure.

Biographical information for Mr. Musso is set forth in Fulcrum’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2026, and is incorporated herein by reference. Mr. Musso will not receive any additional compensation in connection with this appointment. There is no arrangement or understanding between Mr. Musso and any other persons, respectively, pursuant to which he was appointed as principal accounting officer. There are no family relationships among any of Fulcrum’s directors or executive officers and Mr. Musso, and Mr. Musso does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FULCRUM THERAPEUTICS, INC.
Date:	August 10, 2026	By:	/s/ Alex C. Sapir
			Name: Alex C. Sapir Title: President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.5 KB